

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof.
2. (Original): The pharmaceutical composition according to claim 1, comprising (*R*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine substantially free of the corresponding (*S*)-enantiomer; or a pharmaceutically acceptable salt thereof.
3. (Original): The composition according to claim 2 wherein the amount of (*R*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 85% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.
4. (Original): The composition according to claim 3 wherein the amount of (*R*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 90% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.
5. (Original): The composition according to claim 4 wherein the amount of (*R*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 95% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

6. (Original): The composition according to claim 5 wherein the amount of (*R*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 99% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

7. (Original): The pharmaceutical composition according to claim 1, comprising (*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine substantially free of the corresponding (*R*)-enantiomer; or a pharmaceutically acceptable salt thereof.

8. (Original): The composition according to claim 7 wherein the amount of (*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 85% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

9. (Original): The composition according to claim 8 wherein the amount of (*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 90% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

10. (Original): The composition according to claim 9 wherein the amount of (*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 95% by weight or more of the total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

11. (Original): The composition according to claim 10 wherein the amount of (*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 99% by weight or more of the

total weight of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine.

12. (Original): The pharmaceutical composition according to claim 1, comprising a racemic mixture of the (*R*)- and (*S*)-enantiomers of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof.

Claims 13-21. (Canceled).

22. (Currently Amended): A method of treating [[an]] a thromboxane A<sub>2</sub>-mediated disorder related to platelet aggregation in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 1 sufficient to inhibit thromboxane A<sub>2</sub>-mediated platelet aggregation in said individual.

23. (Currently Amended): A method of treating [[an]] a thromboxane A<sub>2</sub>-mediated disorder related to platelet aggregation in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 2 sufficient to inhibit thromboxane A<sub>2</sub>-mediated platelet aggregation in said individual.

24. (Currently Amended): A method of treating [[an]] a thromboxane A<sub>2</sub>-mediated disorder related to platelet aggregation in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 7 sufficient to inhibit thromboxane A<sub>2</sub>-mediated platelet aggregation in said individual.

25. (Currently Amended): A method of treating [[an]] a thromboxane A<sub>2</sub>-mediated disorder related to platelet aggregation in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 12 sufficient to inhibit thromboxane A<sub>2</sub>-mediated platelet aggregation in said individual.

Claims 26-32. (Canceled).

33. (Currently amended): A method of treating a disorder characterized by convulsive seizures ~~an adenosine-mediated disorder~~ in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 1 sufficient to inhibit convulsive seizures in said individual.

34. (Currently amended): A method of treating a disorder characterized by convulsive seizures ~~an adenosine-mediated disorder~~ in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 2 sufficient to inhibit convulsive seizures in said individual.

35. (Currently amended): A method of treating a disorder characterized by convulsive seizures ~~an adenosine-mediated disorder~~ in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 7 sufficient to inhibit convulsive seizures in said individual.

36. (Currently amended): A method of treating a disorder characterized by convulsive seizures ~~an adenosine-mediated disorder~~ in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 12 sufficient to inhibit convulsive seizures in said individual.

Claims 37-58. (Canceled)